Key facts
- This page summarizes Mark Bodmer's Form 4 filing for Evelo Biosciences, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Nov 2023, 20:32.
Mark Bodmer - 07 Nov 2023 Form 4 Insider Report for Evelo Biosciences, Inc.
- Reporting relationship
- CSO, President of R&D
- Issuer ticker
- N/A
- Reported as of
- 07 Nov 2023
- Net transaction value
- -$1,044
- SEC form
- 4
- Accepted by SEC
- 08 Nov 2023, 20:32:53 UTC
- Prior SEC filing
- 03 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marella Thorell, Attorney-in-Fact for Mark Bodmer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark Bodmer filed Form 4 for Evelo Biosciences, Inc. on 08 Nov 2023.
Change
- Previous filing in this sequence was filed on 03 Nov 2023.
- Current net transaction value: -$1,044.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVLO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,625
- Change %
- +30%
- Price
- Shares after
- 28,895
- Date
- 07 Nov 2023
- Ownership
- Direct
- Footnotes
- F1
EVLO
transaction
Common Stock
Sale
- Transaction value
- $1,044
- Shares
- -3,163
- Change %
- -11%
- Price
- $0.3300
- Shares after
- 25,732
- Date
- 08 Nov 2023
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVLO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -6,625
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 6,625
- Date
- 07 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,625
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
Footnote F4
The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.